3.12%
-23.76%
-93.05%
-97.08%
-97.55%
-99.12%
-99.75%
AI Spotlight on SYRS
Company Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd.
for the development and commercialization of tamibarotene.The company was formerly known as LS22, Inc.and changed its name to Syros Pharmaceuticals, Inc.
in August 2012.Syros Pharmaceuticals, Inc.was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 0.18 |
| Change Percentage | 3.12% |
| Open | 0.17 |
| Previous Close | 0.17 |
| Market Cap ( Millions) | 5 |
| Volume | 969975 |
| Year High | 7.96 |
| Year Low | 0.17 |
| M A 50 | 0.23 |
| M A 200 | 2.98 |
Financial Ratios
| FCF Yield | -2128.40% |
| Dividend Yield | 0.00% |
| ROE | -2746.84% |
| Debt / Equity | -541.45% |
| Net Debt / EBIDTA | -2.14% |
| Price To Book | -0.62 |
| Price Earnings Ratio | -0.07 |
| Price To FCF | -0.05 |
| Price To sales | 12.18 |
| EV / EBITDA | -0.07 |
News
- Nov -14 - Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
- Nov -13 - Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
- Nov -04 - The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
- Nov -03 - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
- Nov -02 - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -31 - Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
- Oct -27 - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
- Oct -26 - The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -23 - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
- Oct -21 - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm
- Oct -20 - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -19 - Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
- Oct -18 - The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -17 - Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
- Oct -14 - The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -13 - Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Reach Out To The Schall Law Firm
- Oct -12 - The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -11 - Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
- Oct -10 - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
- Oct -09 - Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Gene Control Medicines
Expected Growth : 11.3 %
What the company do ?
Gene Control Medicines from Syros Pharmaceuticals, Inc. are novel therapies that selectively regulate gene expression to treat diseases, leveraging pioneering genomics and precision medicine approaches.
Why we expect these perspectives ?
Syros Pharmaceuticals' Gene Control Medicines segment growth of 11.3% is driven by increasing adoption of precision medicine, rising prevalence of genetic disorders, and advancements in gene editing technologies such as CRISPR. Additionally, growing investments in R&D and strategic partnerships are expanding the company's pipeline and accelerating product development.
Syros Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| SY-1424 | A selective inhibitor of the cyclin-dependent kinase 7 (CDK7) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) |
| SY-5609 | A selective inhibitor of the cyclin-dependent kinase 7 (CDK7) for the treatment of solid tumors |
| SY-2101 | A selective inhibitor of the cyclin-dependent kinase 12/13 (CDK12/13) for the treatment of hematological malignancies |
Syros Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Syros Pharmaceuticals, Inc. operates in a highly competitive industry, and there are many substitutes available for its products. However, the company's focus on developing novel therapies and its strong research and development capabilities help to mitigate the threat of substitutes.
Bargaining Power Of Customers
Syros Pharmaceuticals, Inc. has a diverse customer base, and no single customer accounts for a significant portion of its revenue. This reduces the bargaining power of customers.
Bargaining Power Of Suppliers
Syros Pharmaceuticals, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size and reputation, suppliers still have some negotiating power.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market. Syros Pharmaceuticals, Inc. needs to continuously innovate and invest in research and development to stay ahead of new entrants.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and Syros Pharmaceuticals, Inc. faces intense rivalry from established players and new entrants. The company needs to focus on differentiating its products and services to gain a competitive advantage.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 72.33% |
| Debt Cost | 8.26% |
| Equity Weight | 27.67% |
| Equity Cost | 12.64% |
| WACC | 9.47% |
| Leverage | 261.36% |
Syros Pharmaceuticals, Inc. : Quality Control
Syros Pharmaceuticals, Inc. passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OABI | OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies … |
| XERS | Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for … |
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| MNKD | MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Xeris Biopharma
A-Score
1-Year Total Return ->
🥈
MannKind
A-Score
1-Year Total Return ->
🥉
Dianthus Therapeutics
A-Score
1-Year Total Return ->
4
Kymera Therapeutics
A-Score
1-Year Total Return ->
5
OmniAb
A-Score
1-Year Total Return ->
6
